ARTICLE | Company News
Pulmatrix gets portfolio of kinase inhibitors from RespiVert
July 6, 2017 6:32 PM UTC
RespiVert Ltd. granted Pulmatrix Inc. (NASDAQ:PULM) exclusive, worldwide rights to develop and commercialize a portfolio of kinase inhibitors to treat cancer and respiratory diseases. Specifically, Pulmatrix said it will develop the compounds to treat chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF). The biotech plans on combining the candidates with its iSPERSE dry powder delivery technology.
The compounds have been "explored" in Phase I testing and Pulmatrix expects "to quickly move to clinical proof-of concept studies."...